CICT Masterclass NSCLC Stage IV

Information updated on 18 July 2022.

Final registration date: 17 October 2022, subject to availability.

Only in situ.

Before : the medical examiner used to know everything, but one day too late

Nowadays : thanks to molecular biology the pathologist and the molecular doctor know everything before it is too late!

Key Opinion Leaders

Small groups: masterclass limited to 20 participants.

Oncologists, pulmonologists, thoracic surgeons

If you require any specific arrangement to attend this training, please contact us or your training adviser.

Biomarkers

8h30-9h15: Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors (Dr J. Adam)

9h15-9h45: The evolving landscape of biomarker testing  for NSCLC (Dr L. Lacroix ou E.Rouleaux)

9h45-10h15: Medical imaging in personalized medicine (Dr C. Caramella)

 

10h15-10h30: Break

Immune checkpoint inhibitor in stage IV NSCLC

10h30-11h15: Treatment of metastatic NSCLC with PD-L1 expression (Dr P. Lavaud)

11h15-12h00: Treatment of metastatic NSCLC with absent PD-L1 expression (Dr F. Bintein ou B.Besse ou M.Aldea)

12h00-12h45: Primary and adaptive resistance to Immune checkpoint inhibitors in NSCLC (Pr F. Barlesi)

 

12h45-14h00: Lunch

Targeted therapies in stage IV NSCLC

New treatment options for EGFR, ALK and ROS1 NSCLC (B.Besse ou M.Aldea)

Targeted therapy beyond EGFR/ALK/ROS1 NSCLC (D.Planchard)

14h00-14h45: Efficacy of local therapy for oligoprogressive disease  in oncogene-addicted NSCLC (Pr O. Mercier/ Dr S. Mussot)

14h45-15h30: Management of brain metastasis in oncogene-addicted advanced NSCLC (Dr A. Botticella)

15h30-16h00: Molecular mechanism of EGFR and ALK-TKIs resistance in  NSCLC  (Luc Friboulet)